Fig. 3.

Presynaptic modulation by cannabinoid receptor-1 (CB1) receptors does not change during development. A: representative experiments from P8 or P18 rat show that the synthetic CB1 agonist WIN55212-2 elicited a robust suppression of eIPSCs and an increase in the amplitude ratio of 2 closely paired eIPSCs. Traces are average eIPSCs from 20 trials before WIN55212-2 and 10 min after drug application. B: WIN55212-2 produced a 52 ± 7% reduction in eIPSC amplitude in P8 rat and a 46 ± 6% reduction in mature rat (P17-20). There was no significant difference between WIN55212-2 effects in young and mature rats (P = 0.51).